Cargando…

Correction to: Nonacog Beta Pegol: A Review in Haemophilia B

Detalles Bibliográficos
Autor principal:	Syed, Yahiya Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061402/ https://www.ncbi.nlm.nih.gov/pubmed/30003467 http://dx.doi.org/10.1007/s40265-018-0951-1

Ejemplares similares

Nonacog Beta Pegol: A Review in Haemophilia B
por: Syed, Yahiya Y.
Publicado: (2017)

Correction to: Damoctocog Alfa Pegol: A Review in Haemophilia A
por: Paik, Julia, et al.
Publicado: (2019)

Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfa
por: Rendo, Pablo, et al.
Publicado: (2018)

Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study
por: Matino, Davide, et al.
Publicado: (2022)

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2019)

Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients
por: Chan, Anthony K., et al.
Publicado: (2020)

Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B
por: Fukutake, Katsuyuki, et al.
Publicado: (2019)

Damoctocog Alfa Pegol: A Review in Haemophilia A
por: Paik, Julia, et al.
Publicado: (2019)

Correction to: Eftrenonacog Alfa: A Review in Haemophilia B
por: Lamb, Yvette N., et al.
Publicado: (2023)

Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study
por: Simpson, Mindy L, et al.
Publicado: (2019)

Steady-State Plasma Concentrations of Polyethylene Glycol (PEG) are Reached in Children and Adults During Once-Weekly Prophylactic Treatment with Nonacog Beta Pegol (N9-GP)
por: Sternebring, Ola, et al.
Publicado: (2019)

Correction to: DTaP‑IPV‑HepB‑Hib Vaccine (Hexyon(®)): An Updated Review of its Use in Primary and Booster Vaccination
por: Syed, Yahiya Y.
Publicado: (2019)

Correction to: Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
por: Syed, Yahiya Y.
Publicado: (2021)

Correction to: Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
por: Syed, Yahiya Y.
Publicado: (2021)

Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021)

Correction: Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids
por: Syed, Yahiya Y.
Publicado: (2022)

Correction: Estetrol/Drospirenone: A Review in Oral Contraception
por: Lee, Arnold, et al.
Publicado: (2022)

Correction to: Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema
por: Fung, Simon, et al.
Publicado: (2022)

Correction to: Efmoroctocog Alfa: A Review in Haemophilia A
por: Frampton, James E.
Publicado: (2021)

Correction to: SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

Correction to: Regdanvimab: First Approval
por: Syed, Yahiya Y.
Publicado: (2021)

Correction to: Sparsentan: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

Correction to: Perindopril/Indapamide/Amlodipine in Hypertension: A Profile of Its Use
por: Syed, Yahiya Y.
Publicado: (2022)

Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

Correction to: Pegaspargase: A Review in Acute Lymphoblastic Leukaemia
por: Heo, Young-A., et al.
Publicado: (2019)

Correction to: Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use
por: Syed, Yahiya Y.
Publicado: (2023)

Correction to: Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Infammation and Pain Following Ocular Surgery
por: Kang, Connie, et al.
Publicado: (2020)

Correction to: Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data
por: Dattola, Annunziata, et al.
Publicado: (2017)

Correction to: Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia
por: Tiede, Andreas, et al.
Publicado: (2018)

Correction to: Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus
Publicado: (2022)

Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study
por: Windyga, Jerzy, et al.
Publicado: (2020)

Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial
por: Patel, Sunil S., et al.
Publicado: (2023)

Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A
por: Sanabria, Martin, et al.
Publicado: (2021)

Correction: 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis
Publicado: (2018)

Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India
por: Choraria, Nirmalkumar, et al.
Publicado: (2022)

Eftrenonacog Alfa: A Review in Haemophilia B
por: Lamb, Yvette N., et al.
Publicado: (2023)

PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

DTaP-IPV-HepB-Hib Vaccine (Hexyon(®)): An Updated Review of its Use in Primary and Booster Vaccination
por: Syed, Yahiya Y.
Publicado: (2019)

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study
por: Reding, Mark T., et al.
Publicado: (2023)

Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B
por: Windyga, Jerzy, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ff8t9k60vrt2k4dktul70hv0ua